Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | MicrobiomeTrials
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-07-06Est. Completion: 2025-07-22
Enrollment target: 7 participants
Locations
Los Angeles General Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Montefiore Medical Center-Einstein Campus, The Bronx, New York, United States
Montefiore Medical Center - Moses Campus, The Bronx, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in